Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 4,592 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 1 Interventional Results available

Three Way Crossover Closed Loop Study With Xeris Glucagon

NCT03424044
View directory record Official record
Conditions
Type1diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode, XeriSol glucagon
Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine in Veterans With Comorbid ADHD/PTSD

NCT02287038
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 MG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

NCT01144455
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemzar (Gemcitabine), TH-302
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
59
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

NCT04375878
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
MS1819, Porcine PERT
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

NCT05681715
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Orange, California • San Francisco, California • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Phase 3 Interventional

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

NCT06938347
View directory record Official record
Conditions
Right-To-Left Shunt
Interventions
Agitated Saline SoC, ASI-02
Drug
Lead sponsor
Agitated Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

NCT01645085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MCC-based 13% drug loaded tablets, Mannitol-based 38% drug-loaded tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 27, 2026, 7:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Laryngeal Mask Airway (LMA) Unique and the Air-Q Intubating Laryngeal Airway (ILA) in Pediatric Patients

NCT01314248
View directory record Official record
Conditions
Children
Interventions
each child will receive both the LMA and ILA
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 36 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

NCT01707043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Taclonex
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

NCT01194258
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Concord, California • Encino, California • Escondido, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Not applicable Interventional

Optimizing Surgical Decisions in Young Adults With Breast Cancer

NCT06275126
View directory record Official record
Conditions
Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
CONSYDER decision aid
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Crossover Study of Magnesium Supplementation

NCT00737815
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Inflammation
Interventions
Magnesium Citrate: a total of 500 mg elemental magnesium, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Oct 27, 2026, 7:37 PM EDT
Terminated Early Phase 1 Interventional Results available

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

NCT00763035
View directory record Official record
Conditions
Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions
Regadenoson, Dobutamine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

NCT05478863
View directory record Official record
Conditions
Behavioral Pharmacology of Cannabinoids
Interventions
Oral Placebo, Oral THC, Oral CBD, Oral Caffeine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Supplemental Oxygen on Memory Testing in Healthy Adult Volunteers

NCT06555484
View directory record Official record
Conditions
Cognition
Interventions
Cross Over Assignment Supplemental Oxygen and Supplemental Air
Device
Lead sponsor
Inogen Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

NCT05355935
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Brensocatib, Moxifloxacin, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

NCT01591889
View directory record Official record
Conditions
Trichomoniasis
Interventions
Tinidazole
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 7:37 PM EDT
Recruiting Not applicable Interventional

Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder

NCT06660225
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation], Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]
Device
Lead sponsor
Nader Pouratian
Other
Eligibility
22 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

NCT00706225
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene and conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 27, 2026, 7:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Impact of Intraoperative Stretching Microbreaks on Otolaryngologists

NCT04806308
View directory record Official record
Conditions
Postural; Strain
Interventions
Otolaryngology stretching micro-breaks (OSMB)
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

NCT05255276
View directory record Official record
Conditions
Healthy Adults
Interventions
Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 27, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

NCT02034708
View directory record Official record
Conditions
Primary Brain Tumor
Interventions
Dotarem®, Gadovist®/Gadavist®
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 27, 2026, 7:37 PM EDT